Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $449.72M | $-5.37M | $-0.05 |
| 2024 | $371.30M | $4.33M | $0.04 |
| 2023 | $328.20M | $-16.84M | $-0.16 |
| 2022 | $293.56M | $-29.89M | $-0.26 |
| 2021 | $243.48M | $15.68M | $0.13 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $0.01 per share
Typical surprise +38.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.02 vs $0.01miss
- Thu, May 7$0.09 vs $0.02beat
- Thu, Mar 19$0.07 vs $-0.00beat
- Thu, Nov 6$-0.03 vs $-0.01miss
- Thu, Aug 7$-0.09 vs $0.01miss
- Thu, May 8$0.02 vs $0.00beat
Estimates and results for KHTRF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
KHTRFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·5d ago·Neutral
Knight Therapeutics Q2 Earnings Call Highlights Knight Therapeutics TSE: GUD reported record results for the first six months of 2026 and raised its full-year outlook, citing growth in its promoted products, contributions from recent launches and favorable foreign-exchange effects.
View source ↗